GlassScriptPhysician profile
Ulupi A Choksi
NPI 1891851531
$778.44
in general payments reported to CMS, 2019-2025
15 companies · $150 in 2025
The $150 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $135 · 2021: $266 · 2022: $144 · 2023: $34.05 · 2024: $49.89 · 2025: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $233.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $196.11 | 2021-2023 | Rybelsus, Ozempic |
| Apollo Endosurgery US INC | $108.84 | 2022 | |
| Lilly USA, LLC | $108.04 | 2019-2025 | Mounjaro, Zepbound |
| Impulse Dynamics (USA) INC. | $86.60 | 2021 | |
| Abbvie INC. | $65.42 | 2023-2025 | Synthroid |
| Sanofi-Aventis U.S. LLC | $32.71 | 2019-2024 | |
| Neurocrine Biosciences, INC. | $32.55 | 2025 | |
| Xeris Pharmaceuticals, INC. | $32.44 | 2025 | Gvoke Hypopen |
| Amgen INC. | $26.89 | 2025 | Tepezza |
| Abbott Laboratories | $18.49 | 2022 | |
| Valeritas, INC. | $16.73 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $16.58 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.76 | 2019 | |
| Medtronic Minimed, INC. | $12.45 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $10.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ulupi Choksi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.